FibroGen is dedicated to creating innovative, first-in-class medicines for the treatment of chronic and life-threatening or debilitating conditions such as anemia in chronic kidney disease (CKD), anemia in myelodysplastic syndromes (MDS), idiopathic pulmonary fibrosis (IPF), pancreatic cancer, and Duchenne muscular dystrophy (DMD). The products we develop represent more than isolated opportunities or single indications — we see our products as representing broader platforms that enable us to continue to investigate discrete pathways and mediators that are central to multiple diseases.

  • Preclin
  • Phase Ph1
  • Ph2
  • Ph3
United States
  • Ph3
Europe
  • Ph3
China
  • Ph3
Japan
  • Ph3
  • Preclin
  • Phase Ph1
  • Ph2
  • Ph3
United States1
  • Ph2
China2
  • Ph1
  • Preclin
  • Phase Ph1
  • Ph2
  • Ph3
Pancreatic Cancer
  • Ph2
Idiopathic Pulmonary Fibrosis
  • Ph2
Duchenne Muscular Dystrophy
  • Ph2
  • Pilot
  • Pivotal Pivotal
Corneal Blindness
  • Pilot
  • Partnered
  • Wholly-Owned
  • Medical Device

1 IND Approved for Phase 3 Study

2 CTA Approved for Phase 2/3 Study

Roxadustat

Roxadustat is a first-in-class, oral small molecule hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) currently being evaluated in multiple Phase 3 clinical trials globally for the treatment of anemia in patients with chronic kidney disease (CKD). Roxadustat is also in Phase 3 development for treatment of anemia in patients with myelodysplastic syndromes (MDS).

Pamrevlumab

Pamrevlumab, our proprietary fully human antibody, represents a potential treatment for a broad array of fibrotic and proliferative disorders that affect organ systems throughout the body.

FG-5200

We are developing FG-5200, a biosynthetic cornea containing our proprietary recombinant human collagen, for the treatment of corneal blindness.